Rapid Micro Biosystems, Inc. Overview
Pro stress-test →Rapid Micro Biosystems provides mission-critical automation solutions for pharmaceutical manufacturing, with its flagship Growth Direct system automating manual microbial quality control (MQC) testing workflows. The company serves critical quality control functions in the manufacturing of biologics, vaccines, cell and gene therapies, and sterile injectables.
Strategic Profile
Pro stress-test →Rising demand for automated, data-driven microbiology QC and regulatory shifts support strong system placements and recurring consumables revenue, while strategic partnerships and operational efficiencies drive expanded commercial reach and margin expansion. The company operates with a recurring revenue model combining hardware systems with proprietary consumables and software solutions.
Competitive Landscape
Pro stress-test →RPID operates in the automated microbial testing market for pharmaceutical manufacturing QC. Key competitors include other automation and laboratory testing providers serving pharmaceutical QC needs, though RPID's specialized focus on microbial detection and platform approach provides differentiation. The market benefits from regulatory tailwinds driving adoption of automated solutions.
Industry Context
Rapid Micro Biosystems, Inc. operates in Life Sciences Technology / Pharmaceutical Manufacturing Equipment.
Key facts
Founded: 2006 · Headquarters: Lexington, Massachusetts · Revenue: $33M (2025 guidance) · Market cap: $0.18B